News

Collaboration aims to acquire all outstanding stock of Afferent in exchange for an upfront payment of $500 million in cash.

Collaboration aims to focus on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of HAE and DME.

Company will invest $15 million in its Steinbach, Manitoba facility including $7 million to upgrade product manufacturing technology and $8 million for the transfer of North American production of Xifaxan® and Apriso®.

Pioneering public-private cancer initiative with unified leadership committed to changing the course of cancer care.

The companies have announced that they have entered into an agreement that further explores hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis (TB).

Company has announced partnership with Marchesini, SEA Vision and TraceLink to introduce new serialisation capabilities.

Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.

Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.

Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.

Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.